Senores Pharma Share Price Hits Record High After Strong Q1 FY26 Results

Market Performance

Senores Pharma share price surged sharply in Thursday’s trading session, hitting a record high following the announcement of robust Q1 FY26 financial results.

• The stock rose up to 13% intraday, touching ₹686 apiece
• It opened at ₹648 on Thursday, compared to the previous close of ₹608.95
• As of 1:40 PM, Senores Pharma shares were trading 12.65% higher

The pharma stock has shown stellar performance since its debut in December 2024, doubling investors' money within just seven months.

Main News

Senores Pharma's share price rally comes on the back of impressive Q1 earnings, showcasing solid year-on-year and sequential growth across key metrics.

The company’s consistent focus on regulated markets and strong operational efficiency contributed significantly to its performance in Q1 FY26.

Financial Performance Overview

Revenue

• Total revenue stood at ₹137.99 crore
• YoY Growth: 72%
• QoQ Growth: 21%

EBITDA

• Reported EBITDA: ₹34.16 crore
• YoY Growth: 60%
• QoQ Growth: 76%

EBITDA Margins

• Margins recovered 45% QoQ to reach 25%
• However, YoY margins declined by 7%

Net Profit

• Net profit rose to ₹21.18 crore
• YoY Increase: 94%
• QoQ Increase: 18%

Segment-Wise Revenue Breakdown

Regulated Markets

• Contribution: 65% of total sales
• Revenue: ₹90 crore
• YoY Growth: 69%
• QoQ Growth: 40%

Emerging Markets

• Contribution: 21%
• Revenue: ₹29 crore
• YoY Growth: 32%
• QoQ Decline: 21%

Other Markets

• Contribution: 14%
• Revenue: ₹18.9 crore
• YoY Growth: 264%
• QoQ Decline: 2%

Company Details

Senores Pharma is a growing name in the pharmaceutical space, with a focus on both regulated and emerging markets. In Q1 FY26, the company:

• Launched 2 new ANDA products in regulated markets
• Received approval for 4 additional ANDAs
• Strengthened its product pipeline with a strategic focus on US government and retail channels
• Emphasized its ability to manufacture and supply controlled substances in the US market

The company’s stronghold in the government contract space offers a clear competitive advantage in regulated territories.

Summary

Senores Pharma share price witnessed a sharp rally following a solid Q1 FY26 performance. Backed by 72% revenue growth, a 94% increase in net profits, and strong EBITDA expansion, the stock has delivered substantial value since its IPO in December 2024.

With over ₹137 crore in quarterly revenue, strong segmental contributions, and sustained growth across markets, Senores Pharma continues to capture investor interest.

The consistent upward trajectory in the Senores Pharma share price underlines its financial resilience and operational strength, positioning it as one of the promising pharma players in the market.